Azitra, Inc. (NYSEAMERICAN:AZTR) Sees Significant Growth in Short Interest

Azitra, Inc. (NYSEAMERICAN:AZTR) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 102,100 shares, a growth of 133.6% from the February 29th total of 43,700 shares. Based on an average daily volume of 418,500 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.5% of the shares of the stock are sold short.

Azitra Price Performance

AZTR traded up $0.00 during trading on Thursday, reaching $0.21. The company had a trading volume of 231,320 shares, compared to its average volume of 457,896. Azitra has a 52 week low of $0.18 and a 52 week high of $5.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.58 and a current ratio of 1.58.

Insiders Place Their Bets

In other news, CEO Francisco D. Salva bought 333,300 shares of the stock in a transaction dated Tuesday, February 13th. The stock was purchased at an average cost of $0.30 per share, for a total transaction of $99,990.00. Following the transaction, the chief executive officer now owns 338,300 shares of the company’s stock, valued at $101,490. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders acquired 351,600 shares of company stock worth $105,480 in the last three months.

Institutional Trading of Azitra

Institutional investors have recently bought and sold shares of the stock. Warberg Asset Management LLC lifted its position in Azitra by 20.7% in the third quarter. Warberg Asset Management LLC now owns 35,000 shares of the company’s stock worth $52,000 after buying an additional 6,000 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Azitra in the second quarter worth $57,000. Finally, Knollwood Investment Advisory LLC purchased a new stake in Azitra in the third quarter worth $62,000. 11.16% of the stock is currently owned by institutional investors.

Azitra Company Profile

Azitra, Inc, a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S.